Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I found it sept 13
When is that? Tia
i would wait until they clarify about the reverse split. a reverse split will push this down to new lows. I wish they would get it over with.
* * $ALQA Video Chart 08-28-17 * *
Link to Video - click here to watch the technical chart video
There is news, but no PR yet...
FDA clears Alliqua BioMedical's SilverSeal wound dressing; shares up 32%
Aug. 28, 2017 12:12 PM ET|About: Alliqua BioMedical, Inc. (ALQA)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Alliqua BioMedical (ALQA +31.9%) jumps on more than an 11x surge in volume on the news that the FDA has granted 510(k) clearance for its SilverSeal Hydrogel wound dressing.
SilverSeal, comprised of 1.5% of almost pure silver, promotes wound healing and delivers broad spectrum antimicrobial activity.
Celgene has increased their position in ALQA twice this year if I'm remember correctly...the last increase was at mush higher prices. Only thing I can think of that lift justify the move.
Really! But why up? Cant find any news!
A few months ago the company talked about a reverse split. Has anything ever come of that discussion? Is that why the price is still falling? Anyone know anything?
Maybe that's why there's a ceiling on the price as of late. Either that or Cellgene really sees something they like with Alliqua. I'm hoping for the later.
Gotta breach $1.50. Looking great here!!
$TOPS
2017 Guidance: Product sales: $19.0M - 19.9M; Contract manufacturing sales: $1.4M, down 36% from last year's $2.2M due to loss of a customer
I hope next weeks earnings is positive and/or comes with positive news to move this thing out of the sub $1
Very nice day. Anticipating a break of the 52-week high tomorrow...and a continued run into next week's earnings.
This is a Volcano...Eruption soon
Celgene Buying...I'm Buying $$$
Celgene Connections
Dr. Jerome Zeldis, MD, PhD, Chairman of the Board of Directors
Dr. Jerome Zeldis is the Chief Medical Officer and President of Clinical Development at Sorrento Therapeutics (Nasdaq: SRNE), a biopharmaceutical company developing new treatments for cancer, pain management, inflammation, and autoimmune diseases. [color=red]Prior to joining Sorrento, Dr. Zeldis served as the Chief Medical Officer of Celgene Corporation (Nasdaq: CELG),
Winston Kung, Member, Board of Directors
Winston Kung is the Vice President of Business Development and Global Alliances at Celgene Corporation. He worked previously as the Chief Business Officer at Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation.
https://alliqua.com/about-us/board-of-directors/
CELGENE CORPORATION Owns 18.8%Includes 8,046,100 shares of Common Stock and 979,094 shares of Common Stock underlying warrants that are exercisable immediately ,The percentage ownership is based on 47,959,371 shares of Common Stock outstanding as of June 23, 2017
https://ih.advfn.com/p.php?pid=nmona&article=75124199
On track for a break-out. Consult the charts...its suggesting 'something's up'.
$ALQA
CELGENE CORPORATION Owns 18.8% Includes 8,046,100 shares of Common Stock and 979,094 shares of Common Stock underlying warrants that are exercisable immediately ,The percentage ownership is based on 47,959,371 shares of Common Stock outstanding as of June 23, 2017
https://ih.advfn.com/p.php?pid=nmona&article=75124199
Board of Directors (SEEE Celgene Connections )
Dr. Jerome Zeldis, MD, PhD, Chairman of the Board of Directors
Dr. Jerome Zeldis is the Chief Medical Officer and President of Clinical Development at Sorrento Therapeutics (Nasdaq: SRNE), a biopharmaceutical company developing new treatments for cancer, pain management, inflammation, and autoimmune diseases. [color=red]Prior to joining Sorrento, Dr. Zeldis served as the Chief Medical Officer of Celgene Corporation (Nasdaq: CELG),
Winston Kung, Member, Board of Directors
Winston Kung is the Vice President of Business Development and Global Alliances at Celgene Corporation. He worked previously as the Chief Business Officer at Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation.[/b]
https://alliqua.com/about-us/board-of-directors/
CELGENE CORPORATION Owns 18.8%Includes 8,046,100 shares of Common Stock and 979,094 shares of Common Stock underlying warrants that are exercisable immediately ,The percentage ownership is based on 47,959,371 shares of Common Stock outstanding as of June 23, 2017
https://ih.advfn.com/p.php?pid=nmona&article=75124199
* * $ALQA Video Chart 07-07-17 * *
Link to Video - click here to watch the technical chart video
Wonder if we're about to witness a Celegene take-over? Hmmmm....
Time to load.
A lot of options awarded today.
Based on showing positive adjusted EBITDA for 2 consecutive quarters. I saw awards to 3 executives of 100,000 shares each.
From the filings:
Represents a restricted stock award that is subject to forfeiture until vested. The award vests fully on the date, if any, the Issuer files financial statements with the SEC on Form 10-K or Form 10-Q that report a positive adjusted EBITDA for the Company for two consecutive fiscal quarters, subject to the Reporting Person's continued service through the applicable vesting date and the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan and that certain restricted stock award agreement by and between the Issuer and the Reporting Person, effective as of June 28, 2017.
Alliqua Biomedical (ALQA) Getting Somewhat Positive Media Coverage, Analysis Finds
https://www.americanbankingnews.com/2017/04/08/alliqua-biomedical-alqa-getting-somewhat-positive-media-coverage-analysis-finds.html/amp
* * $ALQA Video Chart 03-29-17 * *
Link to Video - click here to watch the technical chart video
Good read.
Opinion: We’re in the year of the biotech buyout
http://www.marketwatch.com/story/were-in-the-year-of-the-biotech-buyout-and-here-are-five-prime-targets-2017-01-23?siteid=yhoof2
"This means that many drug companies are becoming more and more dependent on a narrower base of products. Celgene $CELG, is a good example. It reported $11.2 billion in revenue last year, and almost $7 billion of that came from Revlimid, a cancer drug."
Below is another insight to what's happening in the current wound industry:
http://www.brocair.com/pdfs/Wound_Care_Market_Report_Mar_2015.pdf
"Overall, the wound care industry is showing renewed signs of growth as the demand for the products remain strong due to the aging population. There will also be a shift in focus in the coming years towards advanced wound care products including biological dressings and negative pressure wound therapy devices."
Article in Barrons
Celgene Shows Savvy as Gilead Keeps Backsliding -- Barrons.com
7:08 am ET March 16, 2017 (Dow Jones) Print
By Ed Lin
When investors buy shares of Celgene, they are not only getting shares of a savvy company, they are also getting a small biotech exchange-traded fund within it.
It is an ETF rather than mutual fund because the portfolio is more of a passive investment than something actively managed.
Unique among the larger biotechs, Celgene's (ticker: CELG) public holdings total more than $1 billion spread across 12 smaller biotechs. According to S&P Capital IQ, it holds stakes of about 10% or more in Agios Pharmaceuticals (AGIO), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), CRISPR Therapeutics (CRSP), Jounce Therapeutics (JNCE), GlobeImmune (GBIM) and Alliqua BioMedical (ALQA).
In fact, Celgene on March 1 disclosed that it doubled the stake in Alliqua to more than 22%. Alliqua, which has been pummeled in recent years, specializes in advanced wound-care solutions.
Celgene itself has healed nicely from the sector rout last year and has proved to be probably the most resilient. We noted last month that it had already broken out to the upside, in technical-analysis terms.
In terms of competing with peers, it has had a much easier time than Gilead Sciences (ticker: GILD), which we recently opined was "the poster child for big biotech's problems." Gilead's pipeline "has yet to produce a follow-up blockbuster to its hepatitis C treatments, its sales have continued to slide, and it has yet to make an acquisition to add growth back into the mix."
Celgene faces similar headwinds in the sense that it derives most of its revenue from a single product, the blood-cancer drug Revlimid. But Celgene was shrewd enough to reach a settlement in late 2015 that delays a generic threat to Revlimid, and sales haven't slowed meaningfully yet.
Joseph Edelman, founder of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, told us in February, "Celgene keeps chugging along. It has a broad pipeline for cancer and autoimmune diseases; it's in cellular therapy, gene therapy. It has a higher multiple but very stable earnings growth. Gilead is very cheap. If the company can acquire something or give people confidence, there is longer-term value after their cure for hepatitis C."
Celgene indeed keeps chugging along -- a remarkable thing in an industry rife with volatility -- while the confidence of Gilead investors continues to wane. Not even news of a raised dividend or buying a priority review voucher to speed up a Food and Drug Administration review lifted Gilead shares.
Celgene shares suffered in the 2016 biotech slump, but its loss of 3.3% was a gentle landing compared with Gilead's 28% dive. The divergence continues in 2017: Celgene is up 9.6% though Wednesday's close while Gilead has slipped 3.6%.
In a market where the winners keep winning, the investment choices of the winners are certainly of interest.
Celgene paid $2 million for four million additional shares of Alliqua in the latter's private placement of 5.5 million shares at 50 cents a pop. The other major buyer was Alliqua Chairman Jerome Zeldis, who bought 400,000 shares for $200,000. Zeldis had spent nearly 20 years at Celgene, most recently as chief medical officer, before leaving in August to join Sorrento Therapeutics (SRNE) as chief medical officer and president of clinical development.
Celgene now holds the equivalent of more than eight million Alliqua shares, including warrants that are exercisable immediately for about a million shares. It is the largest holder of Alliqua shares, with Celgene admirer Perceptive Advisors in second with 1.9 million shares. Zeldis now holds just under 700,000 Alliqua shares.
Celgene's ties to Alliqua date to November 2013 when Celgene invested $6 million in the latter, and Alliqua received the right to develop and market advanced wound-care products Biovance and Extracellular Matrix.
Don't consider Celgene's latest transaction a clear buy signal for Alliqua, however. Keep in mind that its share price has been slashed 84% since the $3.59 purchase price in Celgene's initial investment. Yet analyst optimism abounds for Alliqua. A consensus of analysts polled by S&P Capital IQ holds a Buy rating.
H.C. Wainwright analyst Swayampakula Ramakanth wrote in November that 2017 could be an inflection point for Alliqua with the planned acquisition of Soluble Systems, a Newport News, Va., wound-care firm. Revenue could double and growth would come from "cross-selling synergies between Alliqua and Soluble Systems sales teams," Ramakanth wrote. He reiterated a Buy rating on Alliqua at the time.
Alas, Alliqua wasn't able to secure the financing to buy Soluble and the deal was called off in late February.
As a big biotech with a sizable public portfolio, Celgene embodies Walt Whitman's declaration, "I am large, I contain multitudes." Even as Celgene chugs along, it has components that exemplify the uncertainties of the sector.
Comments? E-mail us at editors@barrons.com
Follow Ed Lin on Twitter
Like Barron's on Facebook
Follow Barron's on Twitter
(END) Dow Jones Newswires
March 16, 2017 07:08 ET (11:08 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
There were 4 MM's bidding 160k each. Guessing it was a message to the shorts...keeping them from playing games here.
Missed it, picked up a few cheapies though. Will see how this plays out, but I'm optimistic.
This is impressive progress. Glad they're starting to get the affirmation f
The marketplace that they deserve. Hope this one rewards you well as a long-time investor. This is the way the markets used to be. Miss those days.
Oh well. GLTA
$ALQA
Followers
|
66
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4871
|
Created
|
05/22/06
|
Type
|
Free
|
Moderators |
Alliqua's core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin. Transdermal delivery has multiple advantages over conventional oral and injection delivery including:
In addition, Alliqua's patch technology can be utilized for the delivery of many drugs, including various proteins that have, until now, necessitated injections or intravenous infusions.
Alliqua intends to capitalize on its technology's other intrinsic benefits in various market verticals in the healthcare industry, including: wound healing, medical diagnostics and cosmeceuticals.
Alliqua, through its wholly owned subsidiary AquaMed, develops, manufactures and markets electron-beam cross-linked sheet gels for use as transdermal delivery of medication, topical application of non-prescription drugs, wound/burn dressings with and without active ingredients, components in certain medical devices, treatments, cosmetics and other commercial products.
Hydrogels are gel-like or colloidal substances made of water and solids. They can be created chemically (through a combination of ultra violet cross-linking and chemical interface), or by mixing polymer and water, and then exposing it to an electron beam creating a "sheet" of water. Alliqua believes that its hydrogels have a competitive advantage, in part due to the following product characteristics: painless adhesion to the human body, stability of form and composition, purity, reproducibility (manufacturing high quality product on a consistent basis), compatibility with active ingredients, and high water content.
Many of the products of Alliqua's competition feature physical characteristics which Alliqua believes are less desirable than its own hydrogels
Subsidiary | Products |
---|---|
Alliqua Biomedical | PHN Patch |
Hydress + Plus | |
Hydress | |
Aquamed Technologies | Contract Manufacturing Services |
Electrode Gel | |
Sheet Hydrogels | |
HepaLife Biosystems | HepaMate® |
RECENT HEADLINES
Thursday, November 15, 2012
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |